Table 23.8.

Studies of prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer

Reference	Type of study	Drug used	Survival (HIPEC vs no HIPEC)	Peritoneal recurrence (HIPEC vs no HIPEC)
Koga et al. [45]	Randomized controlled trial (RCT)	Mitomycin C (MMC)	30 mo: 83% vs 67%	N/A
Hamazoe et al. [46]	RCT	MMC	5 year: 64% vs 52% Median survival: 77 mo vs 66 mo	39% vs 59%
Fujimura et al. [36]	RCT	MMC and cisplatin	3 year: 68% vs 23%	9% vs 22%
Ikeguchi et al. [47]	RCT	MMC	5 year: 51% vs 46%	35% vs 40%
Fujimoto et al. [48]	RCT	MMC	2 year: 88% vs 77% 4 year: 76% vs 58% 8 year: 62% vs 49%	1.4% vs 23%
Hirose et al. [49]	Prospective case control	MMC, cisplatin, and etoposide	3 year: 49% vs 29% 5 year: 39% vs 17% Median survival: 33 mo vs 22 mo	26 vs 45%
Yonemura et al. [50]	RCT	MMC and cisplatin	5 year: 61% vs 42%	13 vs 15%
Kim et al. [51]	Prospective controlled study	MMC	5 year: 33% vs 27%	7.6% vs 25%

Modified from Seshadri and Glehen [40]